The standardization of immunohistochemical detection and interpretation of CD30 expression in lymphomas

Pathology Expert Group CD30-Positive Lymphoma

doi:10.19401/j.cnki.1007-3639.2023.03.005

您当前的位置：

首页 >

文章列表页 >

The standardization of immunohistochemical detection and interpretation of CD30 expression in lymphomas

Specialists' Commentary | 更新时间：2025-12-31

- The standardization of immunohistochemical detection and interpretation of CD30 expression in lymphomas
- China Oncology Vol. 33, Issue 3, Pages: 228-234(2023)
- 作者机构：
- 作者简介：
- 基金信息：
- DOI：10.19401/j.cnki.1007-3639.2023.03.005
  CLC： R
- Received：28 January 2023，
  
  Revised：2023-02-28，
  
  Published：30 March 2023
- 稿件说明：
移动端阅览
Pathology Expert Group CD30-Positive Lymphoma. The standardization of immunohistochemical detection and interpretation of CD30 expression in lymphomas[J]. China Oncology, 2023, 33(3): 228-234.
DOI：

Pathology Expert Group CD30-Positive Lymphoma. The standardization of immunohistochemical detection and interpretation of CD30 expression in lymphomas[J]. China Oncology, 2023, 33(3): 228-234. DOI： 10.19401/j.cnki.1007-3639.2023.03.005.

摘要

CD30可在多种淋巴瘤中表达，其中经典型霍奇金淋巴瘤（classical Hodgkin lymphoma，CHL）和间变性大细胞淋巴瘤（anaplastic large cell lymphoma，ALCL）最为常见。近年来，靶向CD30的抗体药物偶联物维布妥昔单抗已获批应用于复发/难治性CHL和ALCL患者的治疗，并取得显著疗效。然而，该靶向治疗药物能否使其他类型淋巴瘤患者获益目前尚不明确，精确评估CD30表达水平对此类淋巴瘤患者的临床试验和个体化治疗有重要的指导意义。目前，CD30检测仍主要通过免疫组织化学染色的方法，尚缺乏统一、规范的检测流程及结果判读标准。本文通过分析CD30的检测现状，联合多中心研究探索CD30免疫组织化学检测流程及结果判读方法，并结合文献和专家经验，最终达成淋巴瘤CD30免疫组织化学检测及结果判读共识，希望能有助于淋巴瘤CD30表达的规范化检测。

Abstract

CD30 can be expressed in a variety of lymphoma subtypes

among which classical Hodgkin lymphoma (CHL) and anaplastic large cell lymphoma (ALCL) are the most common ones. Recently

Brentuximab vedotin

the antibody-drug conjugate targeting CD30

has been approved in the treatment of patients with refractory and relapsed CHL and ALCL

and has achieved significant curative effect. However

whether CD30-targeted therapy could benefit patients with other types of lymphoma remains largely unknown. Accurate evaluation of the expression level of CD30 may thus have important guiding significance for the clinical trials and individualized treatment of patients with those lymphomas. To date

CD30 detection is mainly via immunohistochemical staining

however

with no unified and standardized process and interpretation method. We herein described the current status on CD30 testing

and explored the procedures of immunohistochemical detection and interpretation of the results through multicentric studies. A consensus was finally reached

which was based on the combination of our research results

literature review

experts’ experience

and internal discussion among the panel members

and might hopefully contribute to standardization of the immunohistochemical detection and interpretation of CD30 expression in lymphomas.

关键词

Keywords

references

SABATTINI E , PIZZI M , TABANELLI V , et al . CD30 expression in peripheral T-cell lymphomas [J ] . Haematologica , 2013 , 98 ( 8 ): e81 - e82 . DOI: 10.3324/haematol.2013.084913 http://doi.org/10.3324/haematol.2013.084913 http://www.haematologica.org/cgi/doi/10.3324/haematol.2013.084913 http://www.haematologica.org/cgi/doi/10.3324/haematol.2013.084913

WANG G N , ZHAO W G , LI L , et al . Prognostic significance of CD30 expression in nasal natural killer/T-cell lymphoma [J ] . Oncol Lett , 2017 , 13 ( 3 ): 1211 - 1215 . DOI: 10.3892/ol.2017.5592 http://doi.org/10.3892/ol.2017.5592 https://www.spandidos-publications.com/10.3892/ol.2017.5592 https://www.spandidos-publications.com/10.3892/ol.2017.5592

HU S M , XU-MONETTE Z Y , BALASUBRAMANYAM A , et al . CD30 expression defines a novel subgroup of diffuse large B-cell lymphoma with favorable prognosis and distinct gene expression signature: a report from the international DLBCL rituximab-CHOP consortium program study [J ] . Blood , 2013 , 121 ( 14 ): 2715 - 2724 . DOI: 10.1182/blood-2012-10-461848 http://doi.org/10.1182/blood-2012-10-461848

FRANCISCO J A , CERVENY C G , MEYER D L , et al . cAC10-vcMMAE, an anti-CD30-monomethyl auristatin E conjugate with potent and selective antitumor activity [J ] . Blood , 2003 , 102 ( 4 ): 1458 - 1465 . DOI: 10.1182/blood-2003-01-0039 http://doi.org/10.1182/blood-2003-01-0039

PRO B , ADVANI R , BRICE P , et al . Brentuximab vedotin (SGN-35) in patients with relapsed or refractory systemic anaplastic large-cell lymphoma: results of a phase Ⅱ study [J ] . J Clin Oncol , 2012 , 30 ( 18 ): 2190 - 2196 . DOI: 10.1200/JCO.2011.38.0402 http://doi.org/10.1200/JCO.2011.38.0402 https://ascopubs.org/doi/10.1200/JCO.2011.38.0402 https://ascopubs.org/doi/10.1200/JCO.2011.38.0402

YOUNES A , GOPAL A K , SMITH S E , et al . Results of a pivotal phase Ⅱ study of brentuximab vedotin for patients with relapsed or refractory Hodgkin’s lymphoma [J ] . J Clin Oncol , 2012 , 30 ( 18 ): 2183 - 2189 .

NORDI Q C . Control N-IQ. CD30 [M ] . 2017 .

LI B , ESCHRICH S A , BERGLUND A , et al . Use of the total cancer care system to enrich screening for CD30-positive solid tumors for patient enrollment into a brentuximab vedotin clinical trial: a pilot study to evaluate feasibility [J ] . JMIR Res Protoc , 2017 , 6 ( 3 ): e45 . DOI: 10.2196/resprot.7289 http://doi.org/10.2196/resprot.7289 http://www.researchprotocols.org/2017/3/e45/ http://www.researchprotocols.org/2017/3/e45/

HIRSCH F R , VARELLA-GARCIA M , BUNN P A Jr , et al . Epidermal growth factor receptor in non-small cell lung carcinomas: correlation between gene copy number and protein expression and impact on prognosis [J ] . J Clin Oncol , 2003 , 21 ( 20 ): 3798 - 3807 . DOI: 10.1200/JCO.2003.11.069 http://doi.org/10.1200/JCO.2003.11.069 https://ascopubs.org/doi/10.1200/JCO.2003.11.069 https://ascopubs.org/doi/10.1200/JCO.2003.11.069

KIM H K , MOON S M , MOON J H , et al . Complete remission in CD30-positive refractory extranodal NK/T-cell lymphoma with brentuximab vedotin [J ] . Blood Res , 2015 , 50 ( 4 ): 254 - 256 . DOI: 10.5045/br.2015.50.4.254 http://doi.org/10.5045/br.2015.50.4.254

PRINCE H M . CD30 As a target for the treatment of cutaneous T-cell lymphoma [J ] . J Clin Oncol , 2015 , 33 ( 32 ): 3691 - 3696 . DOI: 10.1200/JCO.2015.61.9486 http://doi.org/10.1200/JCO.2015.61.9486

XU M L , GABALI A , HSI E D , et al . Practical approaches on CD30 detection and reporting in lymphoma diagnosis [J ] . Am J Surg Pathol , 2020 , 44 ( 2 ): e1 - e14 . DOI: 10.1097/PAS.0000000000001368 http://doi.org/10.1097/PAS.0000000000001368 https://journals.lww.com/10.1097/PAS.0000000000001368 https://journals.lww.com/10.1097/PAS.0000000000001368

《淋巴瘤病理诊断规范》项目组 . 淋巴组织肿瘤病理诊断规范 [J ] . 中华病理学杂志 , 2019 , 48 ( 5 ): 346 - 349 .

The Project Team of Standardization for Diagnosis Tumor Pathology of Lymphomas . Standardization for diagnosis tumor pathology of lymphomas [J ] . Chin J Pathol , 2019 , 48 ( 5 ): 346 - 349 .

李小秋 , CD30阳性淋巴瘤病理专家组. CD30在淋巴瘤中的表达及检测:现状与挑战 [J ] . 中国癌症杂志 , 2022 , 32 ( 6 ): 512 - 518 . DOI: 10.19401/j.cnki.1007-3639.2022.06.005 http://doi.org/10.19401/j.cnki.1007-3639.2022.06.005

LI X Q . CD30 Positive Lymphoma Pathology Expert Group. Detection of CD30 expression in lymphomas: status and challenges [J ] . China Oncol , 2022 , 32 ( 6 ): 512 - 518 .

Views

3566

下载量

CSCD

Alert me when the article has been cited

提交

Tools

Publicity Resources

Detection of CD30 expression in lymphomas: status and challenges

Consistency analysis of PD-L1 immunohistochemistry antibodies in esophageal squamous cell carcinoma

Expression of MMR in 515 cases of endometrioid adenocarcinoma and its correlation with clinicopathological features

Clinical practice optimization exploration and future prospects of autologous hematopoietic stem cell transplantation for lymphoma

Clinicopathological characteristics and prognostic analysis of medullary thyroid carcinoma in children and adolescents

Related Author

Xiaoqiu LI

CD30阳性淋巴瘤病理专家组

Lijun CHEN

Yichen WANG

Qiang ZHENG

Yue WANG

Yan JIN

Yuan LI

Related Institution

Department of Pathology, Fudan University Shanghai Cancer Center; Department ofOncology, Shanghai Medical College, Fudan University

Department of Pathology, Fudan University Shanghai Cancer Center; Department of Oncology, Shanghai Medical College, Fudan University

Department of Pathology, Shengjing Hospital of China Medical University

苏州大学附属第一医院,江苏省血液病研究所,国家血液系统疾病临床医学研究中心

福建医科大学附属肿瘤医院，福建省肿瘤医院病理科

AI问答

⁰